Evidence map›Paper›PMID 36882704›Full record

ArticleBMC infectious diseases2023

Evaluation of under-testing and under-diagnosis of tick-borne encephalitis in Germany.

Katharina Schley, Josephine Friedrich, Andreas Pilz, Liping Huang, Bridget L Balkaran, Martine C Maculaitis, Claudius Malerczyk

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Assessing the annual burden of tick-borne encephalitis virus infections, north-east Italy, 2017 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Katharina SchleyPfizer Pharma GmbH, Linkstr. 10, 17085, Berlin, Germany. Katharina.Schley@pfizer.com.
Josephine FriedrichPfizer Pharma GmbH, Linkstr. 10, 17085, Berlin, Germany.
Andreas PilzPfizer Corporation, Austria Gesellschaft M.B.H., Floridsdorfer Hauptstraße 1, 1210, Vienna, Austria.
Liping HuangPfizer Inc., 235 East 42Nd Street, New York, NY, USA.
Bridget L BalkaranCerner Enviza, 51 Valley Stream Parkway, Malvern, PA, USA.
Martine C MaculaitisCerner Enviza, 51 Valley Stream Parkway, Malvern, PA, USA.
Claudius MalerczykPfizer Pharma GmbH, Linkstr. 10, 17085, Berlin, Germany.
Pfizer (Germany) · DECerner (United States) · USPfizer (Austria) · ATPfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTick-borne encephalitis (TBE), a viral infectious disease affecting the central nervous system, potentially resulting in prolonged neurological symptoms and other long-term sequelae. Case identification can be challenging as TBE can be associated with non-specific symptoms, and even in cases consistent with typical TBE symptoms, the rate of laboratory testing to confirm cases is unknown. This study assessed real-world TBE laboratory testing rates across Germany.

methodsIn this retrospective cross-sectional study, physicians provided data on TBE decision-making, laboratory testing (serological), and diagnostics behavior via in-depth qualitative interviews (N = 12) or a web-based quantitative survey of their patient medical records (N = 166). Hospital-based physicians who specialized in infectious disease, intensive care unit, emergency room, neurology, or pediatrics with experience managing and ordering testing for patients with meningitis, encephalitis, or non-specific central nervous system symptoms in the past 12 months were included. Data were summarized via descriptive statistics. TBE testing and positivity rates were assessed for the aggregate sample of 1400 patient charts and reported by presenting symptoms, region, and tick bite exposure.

resultsTBE testing rates ranged from 54.0% (non-specific neurological symptoms only) to 65.6% (encephalitis symptoms only); the percentage of TBE positive results ranged from 5.3% (non-specific neurological symptoms only) to 36.9% (meningitis symptoms only). TBE testing rates were higher among those with a tick bite history and/or who presented with headache, high fever, or flu-like symptoms.

conclusionsThe findings of this study suggest that patients with typical TBE symptoms are likely under-tested, thus likely leading to under-diagnosis in Germany. To ensure appropriate case identification, TBE testing should be consistently integrated into routine practice for all patients who present with relevant symptoms or exposure to common risk factors.

Indexed as

EncephalitisEncephalitis, Tick-BorneEncephalitis, ViralTick BitesChildCross-Sectional StudiesGermanyHumansRetrospective StudiesCentral nervous systemEncephalitisGermanyMeningitisMyelitisTickTick biteTick borne encephalitisViral testing

Identifiers

PMID36882704
PMCPMC9990549
OpenAlexW4323356403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.